相关类别
General description
Rhodamine B labeled polymyxin B (SRB-PMB) is a fluorescent derivative of Polymyxin B. Rhodamine B polymyxin B is an additional fluorescent derivative of Polymyxin B, along with Dansyl labeled polymyxin B (Product # SBR00029). Both products′ mode of action is in accordance with Polymyxin B activity. Fluorescent antibiotics are obtained by synthetic conjugation of an antibiotic to a fluorophore.
Application
Fluorescent antibiotics can be used for many applications including:
Additional possible applications for Rhodamine B labeled Polymyxin B:
- Antimicrobial resistance research.
- Bacterial visualization and imaging.
- Parent antibiotic mode of action research and new antibiotic discovery.
- Toxicity studies.
- Research of bacterial infections and tracking its uptake in vivo.
Additional possible applications for Rhodamine B labeled Polymyxin B:
- Evaluate LPS binding by FRET (fluorescence resonance energy transfer) studies to form a specific complex between fluorescein (FITC)-tagged LPS and Polymyxin B, indicating direct binding of the antibiotic to the LPS
- Can be applied as a fluorescent probe to study polymyxin mode of action and its pharmacokinetics
- to assess the mitochondrial function of polymyxin B in a kidney cell line (LLC-PK1), suggesting that it changes the mitochondrial membrane polarization.
Analysis Note
- Rhodamine B labeled polymyxin B Ready Made Solution is light sensitive.
- It is recommended to avoid freeze-thaw cycles of Rhodamine B labeled polymyxin B Ready-Made Solution
- Rhodamine B labeled polymyxin B Ready Made Solution (1.1mg/mL) can be diluted 1:100-200 in PBSX1 (Product# D8537) to achieve 0.55-1.1μg/mL final concentration for staining. The above concentration of Rhodamine B labeled polymyxin B was used for Escherichia coli staining (see image)
- Fluorescence Microscopy application: Rhodamine B labeled polymyxin B Ready Made Solution excitation (Ex) wavelength is 550-560nm resulting in emission (Em) range of 580-610nm (λmax=590-600nm)
存储类别
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
P R Schindler et al.
Antimicrobial agents and chemotherapy, 8(1), 95-104 (1975-07-01)
Though the primary action of the cationic antibiotic polymyxin B is against the membrane of susceptible bacteria, severe morphological changes are detected in the cytoplasm. Using fluorescence microscopy and a mono-N-dansyl-polymyxin B derivative, we could demonstrate aggregations of the antibiotic
Kinetics and Mechanism of the Recognition of Endotoxin by Polymyxin B
Thomas C J, et al.
Journal of the American Chemical Society, 120(48), 12428-12434 (1998)
Vincent H Tam et al.
Antimicrobial agents and chemotherapy, 49(9), 3624-3630 (2005-08-30)
Despite limited data, polymyxin B (PB) is increasingly used clinically as the last therapeutic option for multidrug-resistant (MDR) gram-negative bacterial infections. We examined the in vitro pharmacodynamics of PB against four strains of Pseudomonas aeruginosa. Clonal relatedness of the strains
Elizabeth D Hermsen et al.
Infectious disease clinics of North America, 17(3), 545-562 (2004-01-09)
Although the polymyxins seem attractive because of their unique structure and mechanism of action, relatively little is known about this group of antibiotics. Much of the available information is from a different era of medical practice when the manipulation of
Zakuan Z Deris et al.
Bioconjugate chemistry, 25(4), 750-760 (2014-03-19)
The dry antibiotic development pipeline coupled with the emergence of multidrug resistant Gram-negative 'superbugs' has driven the revival of the polymyxin lipopeptide antibiotics. Polymyxin resistance implies a total lack of antibiotics for the treatment of life-threatening infections. The lack of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持